Direct|acting antiviral agents

HCV DAA Classes - Viral Hepatitis and Liver Disease

Classification of Direct-Acting Antiviral Agents in HCV Treatment Regimens - Hepatitis C · NS3/4A protease inhibitors · NS5A polymerase inhibitors ...

Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology ...

Clinical pharmacology of newer DAA. The direct acting antiviral therapy was started when the first-wave, first-generation HCV NS3-4A protease inhibitors ...

Direct-acting antivirals for the treatment of hepatitis C virus infection

Outline · Glecaprevir-pibrentasvir · Sofosbuvir-velpatasvir · Ledipasvir-sofosbuvir · Sofosbuvir-velpatasvir-voxilaprevir · Elbasvir-grazoprevir.

Direct Acting Antivirals | DrugBank Online

Direct Acting Antivirals ; Sofosbuvir, A direct-acting antiviral agent used to treat specific hepatitis C virus (HCV) infections in combination with other ...

Direct-acting antiviral agents - HCV Guidelines

Direct-acting antiviral agents. The DAA agents target multiple steps in the HCV replication life cycle, are highly effective and safe and require a short ...

Direct-acting antiviral therapies for hepatitis C infection - PubMed

Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have delivered high response rates (>95%) and simplified the management of HCV ...

Direct-acting antivirals indicated for treatment of hepatitis C ...

Direct-acting antiviral medicines (including Daklinza, Exviera, Harvoni, Olysio, Sovaldi and Viekirax) are effective treatments for long-term hepatitis C.

Direct-acting antiviral therapies for hepatitis C infection - The Lancet

Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have delivered high response rates (>95%) and simplified the ...

Changes in Use of Hepatitis C Direct-Acting Antivirals After Access ...

The results of this study suggest that there was greater use of DAAs after states relaxed coverage restrictions related to liver disease severity, sobriety, or ...

Direct-Acting Antiviral Therapy for Treatment of Acute and Recent ...

This article describes the natural history and management of acute and recent HCV infection in the era of DAA therapy and outlines a strategy for use of DAA ...

Antiviral drug - Wikipedia

Direct-acting antivirals · Harvoni (sofosbuvir and ledipasvir) · Epclusa (sofosbuvir and velpatasvir) · Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) ...

Direct-acting antiviral medicines

Direct-acting antiviral (DAA) medicines for the treatment of chronic hepatitis C virus (HCV) infection have been associated with reactivation of hepatitis B ...

Direct-Acting Antivirals and Liver and Nonliver Complications and ...

This cohort study of 245 596 adults with CHC found that DAA treatment (vs no treatment) was independently associated with a lower risk of mortality and liver.

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus ...

HCV treatment has rapidly evolved over the past few years beginning with the launch of 2 direct-acting antivirals (DAAs), boceprevir and telaprevir, in 2011 for ...

Chronic Hepatitis C Virus Infection: Developing Direct-Acting ... - FDA

For the purposes of this guidance, the Food and Drug Administration (FDA) defines direct-acting hepatitis C virus (HCV) antivirals as drugs that ...

Direct Acting Antivirals for Pandemic Prevention - Milwaukee ...

Direct-acting antivirals (DAAs) are defined as those that specifically inhibit viral enzymes that are needed for virus replication. Examples include the herpes ...

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis ...

Administration of telaprevir and boceprevir plus peginterferon and ribavirin increased rates of sustained virological response (SVR) in HCV genotype 1-infected ...

HCV eradication induced by direct-acting antiviral agents reduces ...

We demonstrated that eradication of HCV infection with direct-acting antiviral agents reduces the risk of liver cancer by 71%.

Direct-acting antiviral treatment for hepatitis C - The Lancet

Direct-acting antivirals can achieve sustained virological responses or cure in a high (>95%) proportion of patients and have few adverse events ...

Direct-acting antiviral agents for HCV infection affecting people who ...

This Review outlines the epidemiology of HCV among PWID and those receiving OST, clearly defines 'recent PWID' and provides updated information on DAAs for HCV ...